Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis



    CHARLOTTESVILLE, VA, Sept. 9 /CNW/ - Biovista Inc. today announced that
BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant
positive results in the MOG-induced Experimental Allergic Encephalomyelitis
(EAE) murine model of MS. BVA-201 is an existing drug that Biovista
repositioned in MS and is aimed at neuroprotection. It was shown to have both
efficacy in reducing symptoms and no toxic effects in this well established
model of MS.
    "This is our second success in MS in a period of 6 months, with BVA-201
showing efficacy levels closely comparable to those of dexamethasone," said
Aris Persidis, Ph.D., President of Biovista. "Histology results are also
encouraging, since they seem to confirm our expectations regarding the
compound's mechanism of action. What is even more important is that BVA-201
has a known and very favorable safety profile and is already approved for
chronic use," Dr. Persidis added.
    For a non-confidential information pack on BVA-201 contact Biovista at
info@biovista.com.

    About Biovista's BVA-201 trial in the MS EAE-MOG model

    MS is a chronic inflammatory neurological disease. It is the most
frequent non-traumatic disabling neurologic disease among young adults, with
over 2.5 million patients worldwide. In the animal proof-of-concept trial,
BVA-201 was compared to dexamethasone, a potent anti-inflammatory and
immunosuppressive drug that is efficient in accelerating the recovery from MS
relapses but too toxic for chronic use. BVA-201 induced a statistically
significant reduction of EAE severity, the magnitude of which was directly
comparable to that caused by dexamethasone. Furthermore, BVA-201 protected
neural axons and myelin against degeneration, as shown in the histology
analysis performed. This analysis provided strong evidence that the compound
works as a neuroprotective agent as opposed to most currently approved drugs
that target the immune system.

    About Biovista's repositioning pipeline and technology platform

    Biovista applies high-throughput discovery efforts to finding solutions
for commercially relevant, unmet medical needs. Biovista's proprietary
repositioning technology allows the company's experts to perform
mechanism-of-action based analyses and systematically assess clinical outcomes
in any therapeutic area of interest, at relatively low cost and very short
time spans. The company is presently using this platform to develop its own
pipeline of repositioned drugs in areas such as CNS, cardiovascular disease,
oncology and auto-immune diseases.





For further information:

For further information: Dr Aris Persidis, Biovista, Inc., (434)
242-6514, arisp@biovista.com

Organization Profile

BIOVISTA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890